GLP-1s + Testosterone Replacement: Stacking Protocols and Timing

A 49-year-old man starts semaglutide weighing 225 lbs with total testosterone of 310 ng/dL. Nine months later he's at 195 lbs. His testosterone retest comes back at 410 — improved, but still below the "optimal" range his concierge physician is targeting. The question: add TRT, or let the body keep recovering?

This is the single most common clinical decision in men's metabolic medicine in 2026, and it's usually made with inadequate data. TRT clinics are commercially incentivized to start testosterone. GLP-1 telehealth platforms often don't address hormones at all. The man ends up choosing based on marketing rather than physiology.

Here's the framework that actually works — when to stack, when to sequence, and when TRT was never the right answer.

The two-mechanism problem

Low testosterone in men with obesity is almost always driven by two mechanisms that operate simultaneously:

1. Functional (obesity-driven) hypogonadism. Visceral fat produces aromatase, which converts testosterone to estradiol. Insulin resistance suppresses LH signaling from the pituitary. Inflammatory cytokines from adipose tissue inhibit the hypothalamic-pituitary-testicular axis. All reversible.
2. Primary (testicular) hypogonadism. The testes themselves are producing less testosterone regardless of signaling. Age-related, often genetic, sometimes trauma- or treatment-induced. Not reversible by weight loss.

For most men presenting with low T in their 40s and 50s, component #1 dominates. The ENDO 2025 data showed testosterone normalization from 53% to 77% of men on GLP-1 therapy over 18 months — a 24-percentage-point swing achieved without a single testosterone injection.¹

But not 100% of men normalize. Some have both components operating. For that subset, sequencing or stacking becomes the clinical question.

When to sequence: GLP-1 first, TRT only if needed

Most men with obesity-driven low T should start with the GLP-1 alone and retest hormones at 3, 6, and 12 months. Reasons:

• Many men normalize testosterone completely with weight loss alone — TRT was never necessary.
• TRT suppresses endogenous testosterone production and spermatogenesis, which is costly to reverse if the man wanted to preserve fertility.
• Starting TRT locks in a lifetime commitment that may not be needed.
• The downstream metabolic improvements (reduced aromatase, improved LH signaling) take 6–12 months to fully express. Starting TRT too early masks the trajectory.

If testosterone has normalized into the 500–800 ng/dL range by month 12 on GLP-1 alone, you're done with the hormonal question. If it's stuck below 350 ng/dL despite significant weight loss, that's the signal that there's a primary component — and TRT may be appropriate.

When to stack: true mixed presentation

For a smaller subset of men, the clinical picture indicates both mechanisms from the start:

• Severely low baseline testosterone (total T under 200 ng/dL).
• High or high-normal LH, suggesting the pituitary is signaling hard but the testes can't respond — primary testicular failure.
• History of testicular trauma, chemotherapy, radiation, or undescended testes.
• Symptomatic quality-of-life burden that can't wait 12 months — severe depression, marital dysfunction, career-threatening fatigue.
• Older men (60+) where the time cost of waiting may exceed the benefit of sequencing.

In these cases, starting TRT concurrent with the GLP-1 can make sense. The mechanisms are complementary: TRT supports lean-mass preservation during the caloric deficit the GLP-1 creates, while the GLP-1 handles the metabolic and cardiovascular side of the equation.

The Aging Male published a 2025 review explicitly advocating for combined therapy in obese men with established hypogonadism, noting the complementary mechanisms and the additional benefit of TRT supporting bone mineral density and lean mass during weight loss.²

The muscle-preservation angle

One of the strongest arguments for GLP-1 + TRT combination therapy is lean-mass preservation. GLP-1 weight loss typically includes 25–40% lean mass loss.³ Testosterone directly opposes that — increasing muscle protein synthesis, reducing proteolysis, and supporting bone density.

For a 55-year-old man already close to the sarcopenia threshold, TRT during GLP-1 therapy may mean the difference between losing 6 lbs of muscle vs. 2 lbs. Over 20 remaining years, that's functional independence vs. gradual decline.

This doesn't mean every man on a GLP-1 should be on TRT. But for men with both low-T labs and demonstrably low baseline muscle mass, the combination addresses the central risk of the drug class head-on.

Starting TRT while on a GLP-1 — the practical protocol

Key labs to monitor on the stack

The fertility question

TRT forms: injections, gels, pellets, oral

The delivery system matters less than consistency. Common options:

• Testosterone cypionate or enanthate (IM or subcutaneous injection): Most common, most cost-effective, steady levels with twice-weekly dosing.
• Topical gels (AndroGel, Testim, Fortesta): Daily application, steady levels, but transfer risk to partners and children.
• Pellets (Testopel): Implanted every 3–6 months. Set and forget, but dose adjustment requires another procedure.
• Oral testosterone undecanoate (Jatenzo, Kyzatrex, Tlando): FDA-approved oral options. Twice-daily dosing with fatty meals. Newer, more expensive, less long-term data than injections.
• Clomiphene / Enclomiphene: Not TRT — they stimulate endogenous production. Option for men wanting to preserve fertility.

Cost realities

Combined GLP-1 + TRT therapy is not cheap:

• GLP-1 (compounded or covered): $150–$500/month.
• TRT injections with monitoring: $75–$200/month via telehealth, $100–$300/month at a specialized men's clinic.
• Quarterly labs: $150–$300/quarter if not covered by insurance.
• Total monthly run rate: $275–$800/month, long-term.

Insurance coverage is variable. GLP-1s for diabetes are typically covered with prior authorization. TRT for documented hypogonadism is usually covered. The weight-loss indication for GLP-1s is where coverage gets inconsistent.

The bottom line

For most men with obesity-driven low testosterone, a GLP-1 alone handles both problems. Weight comes off, aromatase drops, insulin sensitivity improves, LH signaling normalizes, testosterone climbs into range. No TRT needed, no lifetime commitment, no fertility suppression.

For the smaller subset with a true primary component — severe low-T plus high-normal LH, or established hypogonadism by history — stacking GLP-1 + TRT is clinically sound and produces complementary benefits. Lean mass preservation, faster symptomatic improvement, coordinated metabolic and hormonal optimization.

The wrong move for either group is leading with TRT without addressing the metabolic state. You end up on lifetime hormone therapy for a problem weight loss would have fixed. Sequence matters. Get the workup right before you commit.